Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.44 |
| ▸ | BRD1 | O95696 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 10/20 | 0.41 |
| ▸ | HTR2B | P41595 | 8/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22542057 | 0.85 | BRPF1 (0.47) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL22542060 | 0.85 | BRPF1 (0.47) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL21359240 | 0.84 | HTR2C (0.47) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL19709395 | 0.84 | HTR3E (0.51) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL30952461 | 0.84 | HTR2C (0.47) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL19709331 | 0.84 | HTR2C (0.47) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL21359242 | 0.84 | HTR2C (0.47) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL20883819 | 0.82 | BRPF1 (0.42) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL25823972 | 0.82 | BRPF1 (0.42) | BRPF1BRD1BRD4BRPF3HTR2C | |
| SCHEMBL20884982 | 0.82 | BRPF1 (0.42) | BRPF1BRD1BRD4BRPF3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
| EP-2029609-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146758-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | NR4A1 239/4885BRPF1 3095/4885BRD1 1106/4885 |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | NR4A1 235/4885BRPF1 3124/4885BRD1 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.